Invasive species cause environmental mayhem when they establish themselves in a new ecosystem. But these interlopers can also impact human health directly. Deadly diseases can jump from animals to humans, as the COVID-19 pandemic vividly illustrated.

A novel decentralized clinical trial found that Paxlovid was ineffective in alleviating long COVID symptoms but underscored the importance of a patient-centered approach.

A new study suggests that people in their 50s and older have embraced the ability to send and receive secure medical messages with their doctors and other providers, through the digital patient portals that most health systems and medical offices now offer. The study also suggests that some older adults – including those with very low incomes – find themselves getting billed for these digital interactions.

The technology described uses a nanomechanical platform and tiny cantilevers to detect multiple HIV antigens at high sensitivity in a matter of minutes. These silicon cantilevers are cheap and easy to mass produce and can be readily equipped with a digital readout. Built into a solar-powered device, this technology could be taken to hard-to-reach parts of the world where early detection remains a challenge to deliver fast interventions to vulnerable populations without waiting for a lab.

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study published in the Lancet Haematology suggests.

Pregnancy may offer some protection from developing Long COVID, found a new study led by Weill Cornell Medicine, University of Rochester Medical Center, University of Utah Health and Louisiana Public Health Institute. Previous research has mostly focused on non-pregnant adults affected by Long COVID— a condition lasting for months after a person recovers from SARS-CoV-2 infection.

A new study published in The Lancet Public Health found that tuberculosis diagnoses plummeted as much as 100 percent in Central and North America in 2021, and nearly 87 percent in Western Europe in 2022 (compared to expected levels). This pattern was distinct from tuberculosis diagnoses among the general population, which experienced a decline in 2020, but generally began increasing again in subsequent years. Incarceration levels remained largely consistent from 2020-2022, suggesting that the reduction in reported TB cases was likely due to other factors, such as reduced capacity for prisons to test and diagnose TB during the unprecedented global crisis.